Assessing impact of postoperative outcomes and quality of life on decisional regret after resection of pancreatic ductal adenocarcinoma.

J Judy Li (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) T Thomas M Li (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) A Adam Geffner (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) S Sophie Neugarten (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) C Camilo Correa (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) U Umut Sarpel (Division of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA) D Daniel M Labow (Nuvance Health, Danbury, CT) G Ganesh Gunasekaran M Myron E. Schwartz (Recanati/Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY) P Parissa Tabrizian S Spiros P Hiotis (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) J James O Park (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY) N Noah A Cohen (Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY)

Abstract

699 Background: Surgery is potentially curative for patients with localized pancreatic ductal adenocarcinoma (PDAC). Given the high rate of complications, decline in quality of life (QoL) postoperatively, and high rates of recurrence, clear preoperative communication and expectation setting is critical. This study investigates clinical outcomes that affect postoperative decisional regret (DR) in patients with PDAC. Methods: This mixed-methods study investigates the impact of clinical outcomes and QoL on the degree of DR in patients with PDAC who have undergone curative-intent resection at least 6 months prior to study recruitment. Patients completed validated surveys assessing DR and QoL by the European Organization for Research and Treatment of Cancer (EORTC). Groups are stratified by presence or absence of DR, assessed by the Decisional Regret Scale (DRS). Characteristics and survey scores were compared by chi-square, independent t-test, and median test. Narrative responses were thematically analyzed. Given significant findings, results of this interim analysis are reported below. Results: 45 patients met inclusion criteria and completed all questionnaires. 19 (42.2%) patients expressed regret about their decision to pursue curative-intent surgery, with 5 patients expressing moderate to severe regret (DRS ≥ 25). There was no significant difference in median postoperative timing of survey completion between groups (56 months in DR group vs 34 months, P=0.465). Baseline characteristics, medical treatments, and operative approaches were similar. Both groups had similar recurrence rates at time of survey completion. While 30 and 90 day readmission rates were similar, a greater proportion of the DR group had 30 day complications (42.1% vs 15.4%, P=0.045). Those expressing regret reported poorer physical functional status (mean score 79.30 ± 18.84 vs 92.31 ± 10.27, P=0.011) and greater impact on social activities (mean score 67.54 ± 33.55 vs 84.67 ± 19.19, P=0.038). Thematic analysis of narrative responses revealed that a majority of patients expressed a strong desire to have a greater focus on potential QoL changes during preoperative discussions. Conclusions: Patients expressing postoperative DR experienced more 30 day complications, and still report lasting effects on their current physical status and social activities. This emphasizes the importance of thorough preoperative counseling on surgical risks and potential changes in postoperative QoL so that patients may make the best informed decision.

Article Details

Volume / Issue Vol. 43, Issue 4_suppl
Published February 01, 2025
Pages 699-699
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (13)

J

Judy Li

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

T

Thomas M Li

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

A

Adam Geffner

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

S

Sophie Neugarten

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

C

Camilo Correa

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

U

Umut Sarpel

Division of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

D

Daniel M Labow

Nuvance Health, Danbury, CT

G

Ganesh Gunasekaran

M

Myron E. Schwartz

Recanati/Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY

P

Parissa Tabrizian

S

Spiros P Hiotis

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

J

James O Park

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

N

Noah A Cohen

Department of Surgery, Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY